High dose busulfan, cyclophosphamide and etoposide as a conditioning regimen for autologous progenitor cell transplantation in patients with multiple myeloma.

被引：0
|
作者：
Cogle, CR [1 ]
Moreb, JS [1 ]
Belanger, GL [1 ]
Leather, HL [1 ]
Boyette, RM [1 ]
Finiewicz, K [1 ]
Khan, SA [1 ]
Reddy, VS [1 ]
Wingard, JR [1 ]
机构：
[1] Univ Florida, Shands Canc Ctr, Gainesville, FL USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5343
引用
收藏
页码：368B / 368B
页数：1
相关论文
共 50 条
  • [41] A NOVEL PREPARATORY REGIMEN INCLUDING BUSULFAN, ETOPOSIDE AND CYCLOPHOSPHAMIDE FOR AUTOLOGOUS TRANSPLANTATION IN HODGKIN AND NON-HODGKIN LYMPHOMA AND MULTIPLE MYELOMA
    EACopelan
    BBolwell
    JLKlien
    NKapoor
    BRAvalos
    ChineseMedicalJournal, 1994, (10)
  • [42] Evaluation of busulfan, cyclophosphamide, and etoposide as a preparation regimen for autologous stem cell transplantation in Hodgkin's lymphoma patients
    Bicim, Soykan
    Erkurt, Mehmet Ali
    Kuku, Irfan
    Kaya, Emin
    Berber, Ilhami
    Kaya, Ahmet
    Hidayet, Emine
    Uysal, Ayse
    Sarici, Ahmet
    Ozen, Ilknur Nizam
    IRAQI JOURNAL OF HEMATOLOGY, 2024, 13 (01) : 1 - 6
  • [43] High-dose melphalan and etoposide prior to autologous hematopoietic stem cell transplant is an effective regimen in the treatment of multiple myeloma.
    Briggs, AD
    Taylor, CW
    Sturm, TJ
    Shapiro, TW
    List, AF
    BLOOD, 1998, 92 (10) : 362B - 362B
  • [44] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Monge, Jorge
    Niesvizky, Ruben
    Hsu, Jing Mei
    Shore, Tsiporah
    Van Besien, Koen
    Pearse, Roger
    Mark, Tomer
    Jayabalan, David
    Mayer, Sebastian Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant for multiple myeloma.
    Beaven, Anne W.
    Comeau, Terrance
    Sharf, Andrew
    Moore, Dominic T.
    Serody, Jonathan
    Shea, Thomas C.
    Gabriel, Don A.
    BLOOD, 2006, 108 (11) : 834A - 834A
  • [46] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
  • [47] Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial
    Blanes, Margarita
    de la Rubia, Javier
    Lahuerta, Juan J.
    Gonzalez, Jose D.
    Ribas, Paz
    Solano, Carlos
    Alegre, Adrian
    Sanz, Miguel A.
    LEUKEMIA & LYMPHOMA, 2009, 50 (02) : 216 - 222
  • [48] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Blanes, Margarita
    De la Rubia, Javier
    Lahuerta, Juan J.
    Gonzalez, Juan D.
    Ribas, Paz
    Solano, Carlos
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 307B - 307B
  • [49] Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
    Shimoni, A
    Smith, TL
    Aleman, A
    Weber, D
    Dimopoulos, M
    Anderlini, P
    Andersson, B
    Claxton, D
    Ueno, NT
    Khouri, I
    Donato, M
    Korbling, M
    Alexanian, R
    Champlin, R
    Giralt, S
    BONE MARROW TRANSPLANTATION, 2001, 27 (08) : 821 - 828
  • [50] Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
    A Shimoni
    TL Smith
    A Aleman
    D Weber
    M Dimopoulos
    P Anderlini
    B Andersson
    D Claxton
    NT Ueno
    I Khouri
    M Donato
    M Korbling
    R Alexanian
    R Champlin
    S Giralt
    Bone Marrow Transplantation, 2001, 27 : 821 - 828
12345